Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.645 USD | -2.40% | -7.84% | -21.28% |
May. 02 | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
May. 01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
Business Summary
Number of employees: 330
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell and Gene Therapies
100.0
%
| 130 | 100.0 % | 65 | 100.0 % | -50.42% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 130 | 100.0 % | 65 | 100.0 % | -50.42% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kristin Yarema
CEO | Chief Executive Officer | 53 | 23-03-31 |
Johanna Mylet
DFI | Director of Finance/CFO | 37 | 15-05-31 |
Mark Gergen
CHM | Chairman | 61 | 18-01-31 |
Loren Wagner
COO | Chief Operating Officer | - | 21-02-28 |
Chief Tech/Sci/R&D Officer | - | - | |
Kristin Martin
ADM | Chief Administrative Officer | 49 | 18-12-31 |
Harry Leonhardt
CMP | Compliance Officer | 67 | 20-07-15 |
Sarah Thailing
IRO | Public Communications Contact | - | 20-10-31 |
Lisa Portale
LAW | General Counsel | - | 18-12-31 |
Karen Basbaum
PRN | Corporate Officer/Principal | - | 20-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Marcea Lloyd
BRD | Director/Board Member | 75 | 18-12-31 |
Cynthia Collins
BRD | Director/Board Member | 65 | 21-07-22 |
Mark Gergen
CHM | Chairman | 61 | 18-01-31 |
John Schmid
BRD | Director/Board Member | 61 | 18-07-18 |
Charles Baum
BRD | Director/Board Member | 65 | 22-05-15 |
Rafael Amado
BRD | Director/Board Member | 60 | 23-04-12 |
Kristin Yarema
CEO | Chief Executive Officer | 53 | 23-03-31 |
Luke Corning
BRD | Director/Board Member | 41 | 20-12-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 96,928,203 | 64,197,197 ( 66.23 %) | 0 | 66.23 % |
Company contact information
Poseida Therapeutics, Inc.
9390 Towne Centre Drive Suite 200
92121, San Diego
+858 779 3100
http://www.poseida.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.28% | 256M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- PSTX Stock
- Company Poseida Therapeutics, Inc.